Palmoplantar Pustulosis during Pregnancy Was Successfully Treated with Tofacitinib: A Case Report
Aggravation of PPP during pregnancy is relatively rare. Tofacitinib, as an oral JAK inhibitor, is effective in the treatment of PPP exacerbated during pregnancy, but the risk to mother and child is unknown, and the relationship between tofacitinib and pregnancy outcome should be further investigated.
Authors
- J. Cheng-Chung Wei (ORCID: https://orcid.org/0009-0003-8880-2322)
- Xiujuan Hou (ORCID: https://orcid.org/0000-0002-1236-6849)
- Fanzhang Meng (ORCID: https://orcid.org/0009-0008-3427-5666)
- Chen Li (ORCID: https://orcid.org/0000-0002-8527-1680)
- Weizhong Li (ORCID: https://orcid.org/0000-0002-8602-8375)
- Zhimin Lin (ORCID: https://orcid.org/0009-0002-6034-1942)
- Bin Dong (ORCID: https://orcid.org/0000-0002-0349-446X)
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Skin Appendage Disorders
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1159/000544921
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.39